Traditionally one of big pharma’s biggest investors in the clinic, Roche Holding AG has lifted its R&D spending even further this year, due in part to many new Phase III starts in oncology and neuroscience and also in part because potential external M&A plays have become too expensive to justify.
The Swiss pharma’s expenditure on research and development has risen every year since 2017. Last year, Roche's pharmaceuticals division spent...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)